Therapeutic Response

HER2-negative and PR positive status confers therapeutic sensitivity to Everolimus in combination with Exemestane in patients with Invasive Breast Carcinoma.

Statements

Source and description
Afinitor (everolimus) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.
Afinitor (everolimus) [product information]. EMA. The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.